This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Second View: Discussing Gilead’s Twice-Yearly Injection Lenacapavir Phase 3 results for for HIV Prevention.

Ticker(s): GILD

Who's the expert?

Institution: Infectious Disease Consultants Medical Group

  • Infectious Disease Specialist at Infectious Disease Consultants Medical Group
  • Manages about 150 patients with HIV 
  • Familiar with and have prescribed all of the following HIV treatments by Gilead Sciences; Biktarvy, Complera, Descovy, Emtriva, Genvoya, Odefsey, Stribild, Truvada, Tybost, and Viread.

Interview Goal
This conversation will discuss the recent Phase 3 results for Lenacapavir, showing zero infections and 100% efficacy.

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.